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Dear  Editor,  
We  read  with  interest  the  article  “Clinical  outcomes  after  surgery  for  primary  aldosteronism:  
evaluation  of  the  PASO-­‐investigators´consensus  criteria  within  a  worldwide  cohort  of  patients“  by  
Vorselaars  and  collaegues.1  From  their  retrospective  study  the  authors  concluded  that  16%  of  their  
patients  were  incorrectly  or  debatably  classified  using  the  criteria  of  the  PASO  consensus.2    The  
authors  suggested  that  this  was  mainly  due  to  using  a  cut-­‐off  of  ≥20  mmHg  to  classify  a  clinically  
relevant  change  in  systolic  blood  pressure.  In  addition,  the  authors  suggested  that  use  of  
percentages  instead  of  absolute  values  in  change  of  antihypertensive  medication  (daily  defined  
doses)  contributed  to  this  incorrect  classification.  
We  would  like  to  clarify  a  number  of  points:  
1.  The  use  of  office  blood  pressure  measurements  are  notorious  for  their  variability.  This  variability  
may  even  be  exaggerated  in  the  study  because  blood  pressure  (as  main  outcome  parameter)  was  
not  measured  in  a  standardized  way.  This  is  clearly  illustrated  by  the  fact  that  in  27%  of  the  patients  
the  preoperative  blood  pressure  level  was  based  on  only  one  blood  pressure  value  and  this  was  
increased  to  50%  of  patients  for  assessment  of  postoperative  blood  pressure.  The  reliability  and  
accuracy  of  the  changes  in  blood  pressure  in  this  study  are  therefore  questionable.    
  
2.  Related  to  the  previous  point,  a  cut-­‐off  change  in  systolic  blood  pressure  of  10  mmHg,  as  
recommended  by  the  authors,  cannot  be  considered  sufficiently  robust  to  estimate  partial  clinical  
success.  The  cut-­‐off  level  of  20  mmHg  was  selected  from  the  differences  between  blood  pressure  
levels  that  define  blood  pressure  categories  of  hypertension3  and  used  by  the  PASO  group  of  experts  
to  define  criteria  for  clinical  outcomes  with  the  structured  Delphi  method.  The  authors  argue  that  10  
mmHg  is  more  appropriate  than  20  mmHg,  based  on  the  associated  decrease  in  cardiovascular  
morbidity  and  mortality  from  studies  in  patients  with  primary  hypertension.  However,  data  from  
primary  hypertensives  cannot  be  translated  to  patients  with  primary  aldosteronism  in  whom  a  
complete  biochemical  response  to  treatment  is  essential4  (which  was  not  assessed  by  Vorselaars  et  
al.1)  and  who  have  an  increased  cardiovascular  risk  compared  with  patients  with  primary  
hypertension.5  
  
3.    The  PASO  consensus  used  an  absolute  value  of  ≥  0.5  DDD  to  define  a  relevant  change  in  
medication  and  not  a  50%  change.  Thus,  the  authors  have  incorrectly  applied  the  PASO  criteria  to  
evaluate  outcomes.  According  to  table  4,  15  of  their  26  patients  had  a  decrease  in  DDD  of  >0.5  DDD,  
so  these  15  patients  should  be  classified  as  partial  and  not  as  absent  clinical  success.    
  
4.  Finally,  the  heterogeneous  approach  for  the  identification  of  surgically-­‐treatable  patients  (with  
reliance  on  nonfunctional  imaging  in  36%  of  patients)  and  the  considerable  deviation  from  the  PASO  
recommendations  for  the  timeframe  of  follow  up  in  68%  of  patients  underlines  further  the  
inappropriateness  of  comparing  data  from  Vorselaars  et  al.1  with  the  PASO  study.2  
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